Cargando…

New developments in the management of advanced melanoma – role of pembrolizumab

Cancer immunotherapy is now recognized to be fundamental in modern oncology, because immune system recruitment may represent a powerful and innovative strategy in cancer therapy. Pembrolizumab, a highly selective humanized monoclonal antibody directly blocking the interaction between programmed cell...

Descripción completa

Detalles Bibliográficos
Autores principales:	Improta, Giuseppina, Leone, Isabella, Donia, Marco, Gieri, Stefania, Pelosi, Giuseppe, Fraggetta, Filippo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4576895/ https://www.ncbi.nlm.nih.gov/pubmed/26396529 http://dx.doi.org/10.2147/OTT.S72823

Ejemplares similares

Biological insights into BRAF(V600) mutations in melanoma patient: Not mere therapeutic targets
por: Improta, Giuseppina, et al.
Publicado: (2013)

Oral malignant melanoma: A report of two cases with BRAF molecular analysis
por: SOMA, PIER FRANCESCO, et al.
Publicado: (2014)

Spotlight on pembrolizumab in the treatment of advanced melanoma
por: Rajakulendran, Thanashan, et al.
Publicado: (2015)

Challenging the standard of care in advanced melanoma: focus on pembrolizumab
por: Abdul-Karim, Raghad M, et al.
Publicado: (2017)

Efficacy of Pembrolizumab in Advanced Melanoma: A Narrative Review
por: Rizzetto, Giulio, et al.
Publicado: (2023)

Efficacy of pembrolizumab for advanced/metastatic melanoma: a meta-analysis
por: Zhang, Qi, et al.
Publicado: (2020)

Diagnostic Consideration for Sinonasal Wegener's Granulomatosis Clinically Mistaken for Carcinoma
por: La Rosa, Cristina, et al.
Publicado: (2013)

Coexistence of two different mutations in codon 12 of the Kras gene in colorectal cancer: Report of a case supporting the concept of tumoral heterogeneity
por: IMPROTA, GIUSEPPINA, et al.
Publicado: (2013)

Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices
por: Cowey, C. Lance, et al.
Publicado: (2018)

Time to Treatment With Nivolumab or Pembrolizumab for Patients With Advanced Melanoma in Everyday Practice
por: Ksienski, Doran, et al.
Publicado: (2021)

Europe Unites for the Digital Transformation of Pathology: The Role of the New ESDIP
por: Eloy, Catarina, et al.
Publicado: (2021)

Correlation between immune-related adverse events and response to pembrolizumab in advanced melanoma patients
por: Grimaldi, Antonio Maria, et al.
Publicado: (2015)

Correlation between BRAF mutational status and clinical response to pembrolizumab in advanced melanoma patients
por: Simeone, Ester, et al.
Publicado: (2015)

Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm
por: Tsur, Neta, et al.
Publicado: (2019)

Management of Advanced Invasive Melanoma: New Strategies
por: Villani, Alessia, et al.
Publicado: (2023)

Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab‐Treated Advanced Melanoma
por: Chatterjee, MS, et al.
Publicado: (2016)

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
por: Hamid, O, et al.
Publicado: (2019)

A phase Ib study of interleukin-2 plus pembrolizumab for patients with advanced melanoma
por: Silk, Ann W., et al.
Publicado: (2023)

Pembrolizumab: First in Class for Treatment of Metastatic Melanoma
por: Barnhart, Carrie
Publicado: (2015)

Pembrolizumab and tavokinogene telseplasmid electroporation in metastatic melanoma
por: Dollin, Yonatan, et al.
Publicado: (2020)

New developments in the management of head and neck cancer – impact of pembrolizumab
por: Saleh, Khalil, et al.
Publicado: (2018)

Pembrolizumab: Role of Modeling and Simulation in Bringing a Novel Immunotherapy to Patients With Melanoma
por: de Greef, R, et al.
Publicado: (2016)

Correlation between histological grade and positron emission tomography parameters in cervical carcinoma
por: Mocciaro, Vanessa, et al.
Publicado: (2016)

Real-world experience with pembrolizumab in patients with advanced melanoma: A large retrospective observational study
por: Liu, Frank Xiaoqing, et al.
Publicado: (2019)

Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 study
por: Si, Lu, et al.
Publicado: (2022)

Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma
por: Gupta, Mehul, et al.
Publicado: (2023)

Shrinkage of a pituitary metastasis of melanoma induced by pembrolizumab: a case report
por: Giuffrida, Giuseppe, et al.
Publicado: (2021)

Pembrolizumab as first-line treatment for metastatic uveal melanoma
por: Rossi, Ernesto, et al.
Publicado: (2019)

Disseminated blastomycosis in a patient on pembrolizumab for metastatic melanoma
por: Ferguson, Ian, et al.
Publicado: (2019)

Tumoral Melanosis Associated with Pembrolizumab-Treated Metastatic Melanoma
por: Bari, Omar, et al.
Publicado: (2017)

Pembrolizumab for the treatment of uveal melanoma: A case series
por: Jansen, Yanina Jeanne Leona, et al.
Publicado: (2020)

Remission of a Perimyocardial Melanoma Metastasis With Pembrolizumab Treatment
por: Larsen, Frederik Uttenthal, et al.
Publicado: (2019)

Real-world experience with pembrolizumab toxicities in advanced melanoma patients: a single-center experience in the UK
por: So, Alfred CP, et al.
Publicado: (2018)

Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma
por: Zakharia, Yousef, et al.
Publicado: (2021)

Combination of pembrolizumab plus temozolomide therapy in unresectable and advanced melanoma: a multicenter retrospective analysis in China
por: Hu, Tu, et al.
Publicado: (2021)

Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany
por: Mohr, Peter, et al.
Publicado: (2022)

Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data
por: du Rusquec, Pauline, et al.
Publicado: (2019)

Immunogenicity of pembrolizumab in patients with advanced tumors
por: van Vugt, Marianne J. H., et al.
Publicado: (2019)

Lichen planopilaris associated with pembrolizumab in a patient with metastatic melanoma
por: Cogen, Anna L., et al.
Publicado: (2018)

Identification of neutralising pembrolizumab anti-drug antibodies in patients with melanoma
por: Sasson, S. C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fv5e0kjovbg1h7urf5nuo70ag8